John Choi

John Choi has extensive experience as a healthcare investor, executive and serial entrepreneur. In addition to being a co-founder and the CBO of Hua Medicine, he is a Venture Partner with Fidelity. Previous to Hua, he co-founded Pytho Capital, a research-oriented, life-science specialized hedge fund investing in small-cap, public biotech companies. Before co-founding Pytho Capital, John was a Principal at the storied venture capital firm of Venrock Associates, the venture investing arm of the Rockefellers. During his tenure there, John focused on Venrock's biotechnology and medical device franchises, working actively with portfolio companies such as Coley Pharmaceuticals (acquired by Pfizer NYSE:PFE), Sirna Therapeutics (acquired by Merck NYSE: MRK), Celladon Corporation (NASDAQ:CLDN), and Princeton Lightwave. He was also previously involved with investments in Nanogram Devices Corporation (acquired by Wilson Greatbatch NYSE:GB), Targeted Genetics Corporation (NASDAQ:TGEN) and led the investment in Skinetics Biosciences (acquired by Sirna Therapeutics NASDAQ:RNAI). Prior to Venrock, he worked at the San Francisco offices of TVM Capital, an international venture capital firm with offices in North America and Europe. Before embarking on his extensive business and investing experience, John was in academia. He previously served as a Resident in the Departments of Internal Medicine and Genetics at Baylor College of Medicine. He also completed his doctoral thesis at Harvard Medical School conducting nuclear magnetic resonance (NMR) studies of human T-cell surface proteins CD2 and CD4. In addition to his Ph.D. in Biophysics from Harvard University, John received his M.D. from Cornell University Medical College, and his B.S. in Applied Math and Physics from Yale College.